KN 1022
Latest Information Update: 26 Oct 2006
Price :
$50 *
At a glance
- Originator Kyowa Hakko; Millennium Pharmaceuticals
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Platelet-derived growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Cancer; Coronary artery restenosis
Most Recent Events
- 26 Oct 2006 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
- 26 Oct 2006 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 26 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)